Abstract
The rapid emergence of new anticancer agents is a tremendous challenge for basic, pre-clinical and clinical research to evaluate and eventually integrate these new agents into clinical routine. Standardized, well-established in vitro and in vivo methods are available for the experimental evaluation of new anticancer agents. A step-wise procedure from in vitro to in vivo experiments using non-functional, functional non-clonogenic and, if applicable, clonogenic assays allows reduction of the number of promising agents for further clinical testing.
Footnotes
- Received November 10, 2004.
- Accepted November 25, 2004.
- Copyright © 2005 The Author(s). Published by the International Institute of Anticancer Research.
In this issue
Jump to section
Related Articles
Cited By...
- Cell Death Identification in Anticancer Therapy--Response
- Culture Dimensionality Influences the Resistance of Glioblastoma Stem-like Cells to Multikinase Inhibitors
- In Vitro and In Vivo Experimental Models as Tools to Investigate the Efficacy of Antineoplastic Drugs on Urinary Bladder Cancer
- Danthron Inhibits Murine WEHI-3 Cells In Vivo, and Enhances Macrophage Phagocytosis and Natural Killer Cell Cytotoxic Activity in Leukemic Mice
- A. cantoniensis Inhibits the Proliferation of Murine Leukemia WEHI-3 Cells In Vivo and Promotes Immunoresponses In Vivo
- Gallic Acid Inhibits Murine Leukemia WEHI-3 Cells In Vivo and Promotes Macrophage Phagocytosis